Safety of ziv-aflibercept in retinal diseases in a Ghanaian population.

Trial Profile

Safety of ziv-aflibercept in retinal diseases in a Ghanaian population.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top